HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Proteome Sciences plc


Latest From Proteome Sciences plc

INTERVIEW: Pre Diagnostics takes new approach to Alzheimer's blood test

As the focus in Alzheimer's moves ever more towards treating early disease, there has been a parallel upswing in diagnostics companies and researchers developing blood tests for Alzheimer's disease. One firm, Norway's Pre Diagnostics, is taking a different approach that it believes will give it the edge over its rivals. Madeleine Armstrong spoke to chief scientific officer Frank Swenson

Neurology Norway

Biomarker study raises hopes for Alzheimer's blood test

Research led by UK company Proteome Sciences and King's College London could lead to a clinical blood test for Alzheimer's disease within five years, and, more immediately, could be helpful in selecting patients for clinical trials of new drugs for the condition. Given the enormous failure rate for drug trials in this indication, it is thought that recruiting patients to drug trials earlier in the disease process before irreversible damage is caused could prove more effective, especially as it is thought that Alzheimer's can be asymptomatic for up to ten years.


SensiDerm Assay Could Fill Void For Non-Animal Allergy Test In EU

U.K-based firm Proteome Sciences eyes the niche for a non-animal sensitivity test. Cosmetics Europe names its SensiDerm assay a first priority for funding.

Proteome advances CK1D inhibitors in Tau approach to Alzheimer's

The proteomics and peptidomics company Proteome Sciences is looking for pharma company partners to take its novel CK1D inhibitors into the clinic in Alzheimer's disease after achieving in vivo proof of concept for the oral compounds.

See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Other Names / Subsidiaries
    • Electrophoretics Ltd